Bayer Launches Phase IIa Trial of BAY 3401016 for Alport Syndrome
Bayer AG has initiated a Phase IIa clinical trial for BAY 3401016, targeting Semaphorin 3A in Alport Syndrome. The ASSESS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BAY 3401016 in adult patients. The drug has received Fast Track and Orphan Drug Designation from the U.S. FDA. The study has just commenced, and results are not yet available.
Bayer AG has announced the initiation of a Phase IIa clinical trial for BAY 3401016, an investigational monoclonal antibody developed to target Semaphorin 3A (Sema3A), a protein believed to play a role in the progression of kidney damage in Alport Syndrome. The ASSESS trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of BAY 3401016 in adult patients with Alport Syndrome, a rare genetic disorder that leads to progressive kidney failure. BAY 3401016 has received Fast Track and Orphan Drug Designation from the U.S. FDA. The results of this research have not yet been presented, as the study has only recently commenced. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203769695) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
